{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:26:48Z","timestamp":1788830808080,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U2RTW010673"],"award-info":[{"award-number":["U2RTW010673"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI089696"],"award-info":[{"award-number":["U19AI089696"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI129387"],"award-info":[{"award-number":["U19AI129387"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa","award":["107740\/Z\/15\/Z"],"award-info":[{"award-number":["107740\/Z\/15\/Z"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Artemisinin-based combination therapy (ACT) was deployed in 2005 as an alternative to chloroquine and is considered the most efficacious treatment currently available for uncomplicated falciparum malaria. While widespread artemisinin resistance has not been reported to date in Africa, recent studies have reported partial resistance in Rwanda. The purpose of this study is to provide a current systematic review and meta-analysis on ACT at Mali study sites, where falciparum malaria is highly endemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review of the literature maintained in the bibliographic databases accessible through the PubMed, ScienceDirect and Web of Science search engines was performed to identify research studies on ACT occurring at Mali study sites. Selected studies included trials occurring at Mali study sites with reported polymerase chain reaction (PCR)-corrected adequate clinical and parasite response rates (ACPRcs) at 28\u00a0days. Data were stratified by treatment arm (artemether\u2013lumefantrine (AL), the first-line treatment for falciparum malaria in Mali and non-AL arms) and analysed using random-effects, meta-analysis approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 11 studies met the inclusion criteria, and a risk of bias assessment carried out by two independent reviewers determined low risk of bias among all assessed criteria. The ACPRc for the first-line AL at Mali sites was 99.0% (95% CI (98.3%, 99.8%)), while the ACPRc among non-AL treatment arms was 98.9% (95% CI (98.3%, 99.5%)). The difference in ACPRcs between non-AL treatment arms and AL treatment arms was not statistically significant (p\u2009=\u2009.752), suggesting that there are potential treatment alternatives beyond the first-line of AL in Mali.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ACT remains highly efficacious in treating uncomplicated falciparum malaria in Mali. Country-specific meta-analyses on ACT are needed on an ongoing basis for monitoring and evaluating drug efficacy patterns to guide local malaria treatment policies, particularly in the wake of observed artemisinin resistance in Southeast Asia and partial resistance in Rwanda.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-021-03890-0","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T04:16:54Z","timestamp":1630297014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Mali: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Fatoumata O.","family":"Maiga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou","family":"Wele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sounkou M.","family":"Toure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makan","family":"Keita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheick Oumar","family":"Tangara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi R.","family":"Refeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumar","family":"Thiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassoum","family":"Kayentao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahamadou","family":"Diakite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Dara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahamoudou","family":"Toure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issaka","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulaye","family":"Djimd\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances J.","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seydou O.","family":"Doumbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3941-3772","authenticated-orcid":false,"given":"Jeffrey G.","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"3890_CR1","unstructured":"WHO. Malaria: key facts. Geneva, World Health Organization, 2020. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/malaria."},{"key":"3890_CR2","unstructured":"WHO. World Malaria Report 2018. Geneva, World Health Organization, 2018. https:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2018\/en\/."},{"key":"3890_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJM200101253440403","volume":"344","author":"A Djimd\u00e9","year":"2001","unstructured":"Djimd\u00e9 A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourt\u00e9 Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001;344:257\u201363.","journal-title":"N Engl J Med"},{"key":"3890_CR4","doi-asserted-by":"publisher","first-page":"8907","DOI":"10.1038\/s41598-020-65553-5","volume":"10","author":"MA Diallo","year":"2020","unstructured":"Diallo MA, Yade MS, Ndiaye YD, Diallo I, Diongue K, Sy SA, et al. Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal. Sci Rep. 2020;10:8907.","journal-title":"Sci Rep"},{"key":"3890_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1475-2875-10-116","volume":"10","author":"AE Frosch","year":"2011","unstructured":"Frosch AE, Venkatesan M, Laufer MK. Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Malar J. 2011;10:116.","journal-title":"Malar J"},{"key":"3890_CR6","unstructured":"WHO. Surge in demand leads to shortage of artemisinin-based combination therapy for malaria. Geneva, World Health Organization, 2004. https:\/\/www.who.int\/mediacentre\/news\/releases\/2004\/pr77\/en\/."},{"issue":"5 Pt 2","key":"3890_CR7","doi-asserted-by":"publisher","first-page":"64r","DOI":"10.1203\/PDR.0b013e3181a0977e","volume":"65","author":"MA Travassos","year":"2009","unstructured":"Travassos MA, Laufer MK. Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations. Pediatr Res. 2009;65(5 Pt 2):64r\u201370r.","journal-title":"Pediatr Res"},{"key":"3890_CR8","volume-title":"Malaria: Q&A on artemisinin resistance","author":"WHO","year":"2019","unstructured":"WHO. Malaria: Q&A on artemisinin resistance. Geneva: World Health Organization; 2019."},{"issue":"6 Suppl","key":"3890_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4269\/ajtmh.2007.77.193","volume":"77","author":"A Bosman","year":"2007","unstructured":"Bosman A, Mendis KN. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg. 2007;77(6 Suppl):193\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"3890_CR10","volume-title":"Overview of malaria treatment","author":"WHO","year":"2018","unstructured":"WHO. Overview of malaria treatment. Geneva: World Health Organization; 2018."},{"key":"3890_CR11","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1016\/S2214-109X(16)30236-4","volume":"5","author":"HM Mavoko","year":"2017","unstructured":"Mavoko HM, Nabasumba C, da Luz RI, Tinto H, D\u2019Alessandro U, Kambugu A, et al. Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. Lancet Global Health. 2017;5:e60\u20138.","journal-title":"Lancet Global Health"},{"key":"3890_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5897\/CRO16.0110","volume":"8","author":"S Dama","year":"2017","unstructured":"Dama S, Djimde AA, Doumbo OK. Methods for monitoring artemisinin-based combination therapies efficacy. Clin Rev Opin. 2017;8:1\u201313.","journal-title":"Clin Rev Opin"},{"key":"3890_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12936-016-1408-1","volume":"15","author":"J Pousibet-Puerto","year":"2016","unstructured":"Pousibet-Puerto J, Salas-Coronas J, S\u00e1nchez-Crespo A, Molina-Arrebola MA, Soriano-P\u00e9rez MJ, Gim\u00e9nez-L\u00f3pez MJ, et al. Impact of using artemisinin-based combination therapy (ACT) in the treatment of uncomplicated malaria from Plasmodium falciparum in a non-endemic zone. Malar J. 2016;15:339.","journal-title":"Malar J"},{"issue":"6 Suppl","key":"3890_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4269\/ajtmh.2007.77.181","volume":"77","author":"F Nosten","year":"2007","unstructured":"Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2007;77(6 Suppl):181\u201392.","journal-title":"Am J Trop Med Hyg"},{"key":"3890_CR15","doi-asserted-by":"publisher","first-page":"e6682","DOI":"10.1371\/journal.pone.0006682","volume":"4","author":"Z Premji","year":"2009","unstructured":"Premji Z, Umeh RE, Owusu-Agyei S, Esamai F, Ezedinachi EU, Oguche S, et al. Chlorproguanil\u2013dapsone-artesunate versus artemether\u2013lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. PLoS ONE. 2009;4:e6682.","journal-title":"PLoS ONE."},{"key":"3890_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1475-2875-13-9","volume":"13","author":"D Djall\u00e9","year":"2014","unstructured":"Djall\u00e9 D, Njuimo SP, Manirakiza A, Laganier R, Le Faou A, Rogier C. Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial. Malar J. 2014;13:9.","journal-title":"Malar J"},{"key":"3890_CR17","unstructured":"WHO. The \"World malaria report 2019\" at a glance. Geneva, World Health Organization, 2019. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/world-malaria-report-2019."},{"key":"3890_CR18","unstructured":"President\u2019s Malaria Initiative. Mali 2018. https:\/\/www.pmi.gov\/docs\/default-source\/default-document-library\/country-profiles\/mali_profile.pdf?sfvrsn=24."},{"key":"3890_CR19","unstructured":"Kone D, Coulibaly D, Doumbo O, Fall IS, Kibuchi E, Mitto B, et al. An epidemiological profile of malaria in Mali. PNLP, MRTC and INFORM. 2015. http:\/\/www.inform-malaria.org\/wp-content\/uploads\/2015\/03\/Mali-Malaria-Epi-Profile-Report_030315.pdf."},{"key":"3890_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12936-018-2636-3","volume":"18","author":"RA Ashton","year":"2019","unstructured":"Ashton RA, Doumbia B, Diallo D, Druetz T, Florey L, Taylor C, et al. Measuring malaria diagnosis and treatment coverage in population-based surveys: a recall validation study in Mali among caregivers of febrile children under 5 years. Malar J. 2019;18:3.","journal-title":"Malar J"},{"key":"3890_CR21","unstructured":"WHO. Mali: Malaria country profile. Geneva, World Health Organization, 2017. https:\/\/www.who.int\/gho\/countries\/mli\/country_profiles\/en\/."},{"key":"3890_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(03)15162-8","volume":"363","author":"M Adjuik","year":"2004","unstructured":"Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004;363:9\u201317.","journal-title":"Lancet"},{"key":"3890_CR23","first-page":"CD007483","volume":"2009","author":"D Sinclair","year":"2009","unstructured":"Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. 2009;2009:CD007483.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"3890_CR24","doi-asserted-by":"publisher","first-page":"ofv170","DOI":"10.1093\/ofid\/ofv170","volume":"3","author":"RJ Burger","year":"2016","unstructured":"Burger RJ, van Eijk AM, Bussink M, Hill J, Ter Kuile FO. Artemisinin-based combination therapy versus quinine or other combinations for treatment of uncomplicated Plasmodium falciparum malaria in the second and third trimester of pregnancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016;3(1):ofv170.","journal-title":"Open Forum Infect Dis."},{"key":"3890_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1473-3099(16)30378-4","volume":"17","author":"J Gutman","year":"2017","unstructured":"Gutman J, Kovacs S, Dorsey G, Stergachis A, Ter Kuile FO. Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17:184\u201393.","journal-title":"Lancet Infect Dis"},{"key":"3890_CR26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00436-016-5353-2","volume":"116","author":"LJ Zhou","year":"2017","unstructured":"Zhou LJ, Xia J, Wei HX, Liu XJ, Peng HJ. Risk of drug resistance in Plasmodium falciparum malaria therapy-a systematic review and meta-analysis. Parasitol Res. 2017;116:781\u20138.","journal-title":"Parasitol Res"},{"key":"3890_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12936-017-1963-0","volume":"16","author":"S Whegang Youdom","year":"2017","unstructured":"Whegang Youdom S, Tahar R, Basco LK. Comparison of anti-malarial drugs efficacy in the treatment of uncomplicated malaria in African children and adults using network meta-analysis. Malar J. 2017;16:311.","journal-title":"Malar J"},{"key":"3890_CR28","first-page":"1","volume":"3","author":"A Talisuna","year":"2014","unstructured":"Talisuna A. The changing landscape of malaria case management in Uganda: decades of struggle with evolving malaria case management strategies and drug policies. Malar Chemother Control Elimin. 2014;3:1.","journal-title":"Malar Chemother Control Elimin"},{"key":"3890_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12936-017-1922-9","volume":"16","author":"EA Gebreyohannes","year":"2017","unstructured":"Gebreyohannes EA, Bhagavathula AS, Seid MA, Tegegn HG. Anti-malarial treatment outcomes in Ethiopia: a systematic review and meta-analysis. Malar J. 2017;16:269.","journal-title":"Malar J"},{"key":"3890_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12936-018-2265-x","volume":"17","author":"I Adam","year":"2018","unstructured":"Adam I, Ibrahim Y, Gasim GI. Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis. Malar J. 2018;17:110.","journal-title":"Malar J"},{"key":"3890_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-018-0259-3","volume":"19","author":"S Whegang Youdom","year":"2019","unstructured":"Whegang Youdom S, Chiabi A, Basco LK. Monitoring the efficacy and safety of artemisinin-based combination therapies: a review and network meta-analysis of antimalarial therapeutic efficacy trials in Cameroon. Drugs R D. 2019;19:1\u201314.","journal-title":"Drugs R D"},{"key":"3890_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12936-021-03809-9","volume":"20","author":"MS Cherif","year":"2021","unstructured":"Cherif MS, Dahal P, Beavogui AH, Delamou A, Lama EK, Camara A, et al. Malaria epidemiology and anti-malarial drug efficacy in Guinea: a review of clinical and molecular studies. Malar J. 2021;20:272.","journal-title":"Malar J"},{"key":"3890_CR33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12936-021-03845-5","volume":"20","author":"C Rasmussen","year":"2021","unstructured":"Rasmussen C, Ringwald P. Is there evidence of anti-malarial multidrug resistance in Burkina Faso? Malar J. 2021;20:320.","journal-title":"Malar J"},{"key":"3890_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12936-021-03585-6","volume":"20","author":"A Gansan\u00e9","year":"2021","unstructured":"Gansan\u00e9 A, Moriarty LF, M\u00e9nard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy and resistance monitoring of artemether\u2013lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018. Malar J. 2021;20:48.","journal-title":"Malar J"},{"key":"3890_CR35","doi-asserted-by":"publisher","first-page":"101919","DOI":"10.1016\/j.parint.2019.04.016","volume":"74","author":"PG Mathenge","year":"2020","unstructured":"Mathenge PG, Low SK, Vuong NL, Mohamed MYF, Faraj HA, Alieldin GI, et al. Efficacy and resistance of different artemisinin-based combination therapies: a systematic review and network meta-analysis. Parasitol Int. 2020;74:101919.","journal-title":"Parasitol Int."},{"key":"3890_CR36","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMc1612765","volume":"376","author":"F Lu","year":"2017","unstructured":"Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;376:991\u20133.","journal-title":"N Engl J Med"},{"key":"3890_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12936-017-1700-8","volume":"16","author":"S Dama","year":"2017","unstructured":"Dama S, Niangaly H, Ouattara A, Sagara I, Sissoko S, Traore OB, et al. Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether\u2013lumefantrine treatment in Mali. Malar J. 2017;16:59.","journal-title":"Malar J"},{"key":"3890_CR38","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120\u20138.","journal-title":"Lancet Infect Dis"},{"key":"3890_CR39","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"3890_CR40","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/S1473-3099(21)00168-7","volume":"21","author":"PJ Rosenthal","year":"2021","unstructured":"Rosenthal PJ. Has artemisinin resistance emerged in Africa? Lancet Infect Dis. 2021;21:1056\u20137.","journal-title":"Lancet Infect Dis"},{"key":"3890_CR41","unstructured":"PRISMA. Transparent reporting of systematic reviews and meta-analyses 2015. http:\/\/www.prisma-statement.org\/PRISMAStatement\/."},{"key":"3890_CR42","first-page":"0919","volume":"2007","author":"D Taylor-Robinson","year":"2007","unstructured":"Taylor-Robinson D, Jones K, Garner P. Malaria: uncomplicated, caused by Plasmodium falciparum. BMJ Clin Evid. 2007;2007:0919.","journal-title":"BMJ Clin Evid"},{"key":"3890_CR43","doi-asserted-by":"crossref","unstructured":"Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019)2019.","DOI":"10.1002\/9781119536604"},{"key":"3890_CR44","unstructured":"StataCorp LLC. Stata 16: Meta-analysis. 2020."},{"key":"3890_CR45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","volume":"72","author":"VN Nyaga","year":"2014","unstructured":"Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72:39.","journal-title":"Arch Public Health"},{"key":"3890_CR46","unstructured":"Cochrane. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials. https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials."},{"key":"3890_CR47","doi-asserted-by":"publisher","first-page":"630","DOI":"10.4269\/ajtmh.2006.75.630","volume":"75","author":"I Sagara","year":"2006","unstructured":"Sagara I, Dicko A, Djimde A, Guindo O, Kone M, Tolo Y, et al. A randomized trial of artesunate\u2013sulfamethoxypyrazine\u2013pyrimethamine versus artemether\u2013lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg. 2006;75:630\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"3890_CR48","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4269\/ajtmh.2008.78.455","volume":"78","author":"AA Djimd\u00e9","year":"2008","unstructured":"Djimd\u00e9 AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, et al. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg. 2008;78:455\u201361.","journal-title":"Am J Trop Med Hyg"},{"key":"3890_CR49","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4269\/ajtmh.2008.79.655","volume":"79","author":"I Sagara","year":"2008","unstructured":"Sagara I, Diallo A, Kone M, Coulibaly M, Diawara SI, Guindo O, et al. A randomized trial of artesunate\u2013mefloquine versus artemether\u2013lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg. 2008;79:655\u201361.","journal-title":"Am J Trop Med Hyg"},{"key":"3890_CR50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1475-2875-8-63","volume":"8","author":"I Sagara","year":"2009","unstructured":"Sagara I, Rulisa S, Mbacham W, Adam I, Sissoko K, Maiga H, et al. Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether\u2013lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial. Malar J. 2009;8:63.","journal-title":"Malar J"},{"key":"3890_CR51","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1475-2875-8-125","volume":"8","author":"JL Ndiaye","year":"2009","unstructured":"Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ\u2013a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar J. 2009;8:125.","journal-title":"Malar J"},{"key":"3890_CR52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4269\/ajtmh.2012.11-0649","volume":"87","author":"I Sagara","year":"2012","unstructured":"Sagara I, Fofana B, Gaudart J, Sidibe B, Togo A, Toure S, et al. Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact. Am J Trop Med Hyg. 2012;87:50\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"3890_CR53","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1473-3099(15)00318-7","volume":"16","author":"I Sagara","year":"2016","unstructured":"Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, et al. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis. 2016;16:189\u201398.","journal-title":"Lancet Infect Dis"},{"key":"3890_CR54","doi-asserted-by":"publisher","first-page":"634","DOI":"10.4269\/ajtmh.15-0503","volume":"94","author":"K Niare","year":"2016","unstructured":"Niare K, Dara A, Sagara I, Sissoko MS, Guindo CO, Cisse NH, et al. In vivo efficacy and parasite clearance of artesunate + sulfadoxine\u2013pyrimethamine versus artemether\u2013lumefantrine in Mali. Am J Trop Med Hyg. 2016;94:634\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"3890_CR55","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1473-3099(17)30365-1","volume":"17","author":"OA Koita","year":"2017","unstructured":"Koita OA, Sangar\u00e9 L, Miller HD, Sissako A, Coulibaly M, Thompson TA, et al. AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. Lancet Infect Dis. 2017;17:1266\u201375.","journal-title":"Lancet Infect Dis"},{"key":"3890_CR56","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12936-018-2496-x","volume":"17","author":"S Dama","year":"2018","unstructured":"Dama S, Niangaly H, Djimde M, Sagara I, Guindo CO, Zeguime A, et al. A randomized trial of dihydroartemisinin-piperaquine versus artemether\u2013lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Malar J. 2018;17:347.","journal-title":"Malar J"},{"key":"3890_CR57","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1475-2875-8-5","volume":"8","author":"K Kayentao","year":"2009","unstructured":"Kayentao K, Maiga H, Newman RD, McMorrow ML, Hoppe A, Yattara O, et al. Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali. Malar J. 2009;8:5.","journal-title":"Malar J"},{"key":"3890_CR58","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/1475-2875-11-364","volume":"11","author":"K Kayentao","year":"2012","unstructured":"Kayentao K, Doumbo OK, P\u00e9nali LK, Offianan AT, Bhatt KM, Kimani J, et al. Pyronaridine-artesunate granules versus artemether\u2013lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J. 2012;11:364.","journal-title":"Malar J"},{"key":"3890_CR59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12936-015-0557-y","volume":"14","author":"H Maiga","year":"2015","unstructured":"Maiga H, Djimde AA, Beavogui AH, Toure O, Tekete M, Sangare CP, et al. Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali. Malar J. 2015;14:64.","journal-title":"Malar J"},{"key":"3890_CR60","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/nyas.12766","volume":"1342","author":"S Takala-Harrison","year":"2015","unstructured":"Takala-Harrison S, Laufer MK. Antimalarial drug resistance in Africa: key lessons for the future. Ann N Y Acad Sci. 2015;1342:62\u20137.","journal-title":"Ann N Y Acad Sci"},{"key":"3890_CR61","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12936-019-2986-5","volume":"18","author":"SAS Diakit\u00e9","year":"2019","unstructured":"Diakit\u00e9 SAS, Traor\u00e9 K, Sanogo I, Clark TG, Campino S, Sangar\u00e9 M, et al. A comprehensive analysis of drug resistance molecular markers and Plasmodium falciparum genetic diversity in two malaria endemic sites in Mali. Malar J. 2019;18:361.","journal-title":"Malar J"},{"key":"3890_CR62","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/10915810490471352","volume":"23","author":"S Ramanathan-Girish","year":"2004","unstructured":"Ramanathan-Girish S, Catz P, Creek MR, Wu B, Thomas D, Krogstad DJ, et al. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques. Int J Toxicol. 2004;23:179\u201389.","journal-title":"Int J Toxicol"},{"key":"3890_CR63","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/13543784.2019.1560419","volume":"28","author":"JB Mengue","year":"2019","unstructured":"Mengue JB, Held J, Kreidenweiss A. AQ-13 - an investigational antimalarial drug. Expert Opin Investig Drugs. 2019;28:217\u201322.","journal-title":"Expert Opin Investig Drugs"},{"key":"3890_CR64","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva, World Health Organization, 2009. https:\/\/www.who.int\/malaria\/publications\/atoz\/9789241597531\/en\/."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03890-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03890-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03890-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T05:08:24Z","timestamp":1630300104000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03890-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3890"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03890-0","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"assertion":[{"value":"26 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work utilized publicly available data from published manuscripts from the publicly available bibliographic databases and did not require ethics approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"356"}}